{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:29Z","timestamp":1793727749845,"version":"4.6.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-00933-6","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T10:18:28Z","timestamp":1747304308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy"],"prefix":"10.1038","volume":"9","author":[{"given":"Yv-Yin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Nan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Hao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"933_CR1","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Progenitor-like exhausted SPRY1(+)CD8(+) T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. Cancer Cell 41, 1852\u20131870.e9 (2023).","journal-title":"Cancer Cell"},{"key":"933_CR2","doi-asserted-by":"publisher","first-page":"eabn6173","DOI":"10.1126\/sciimmunol.abn6173","volume":"8","author":"M van Gulijk","year":"2023","unstructured":"van Gulijk, M. et al. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci. Immunol. 8, eabn6173 (2023).","journal-title":"Sci. Immunol."},{"key":"933_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545\u20131549 (2018).","journal-title":"Nat. Med."},{"key":"933_CR4","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad, G. et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309\u20135337 (2021).","journal-title":"Cell"},{"key":"933_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun, Q. et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct. Target Ther. 8, 320 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"933_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunpaa","year":"2020","unstructured":"Harjunpaa, H. & Guillerey, C. TIGIT as an emerging immune checkpoint. Clin. Exp. Immunol. 200, 108\u2013119 (2020).","journal-title":"Clin. Exp. Immunol."},{"key":"933_CR7","doi-asserted-by":"publisher","first-page":"699895","DOI":"10.3389\/fimmu.2021.699895","volume":"12","author":"Z Ge","year":"2021","unstructured":"Ge, Z. et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. Front Immunol. 12, 699895 (2021).","journal-title":"Front Immunol."},{"key":"933_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang, P. et al. Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark. Res 12, 7 (2024).","journal-title":"Biomark. Res"},{"key":"933_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu, X. et al. Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol. Cancer 22, 93 (2023).","journal-title":"Mol. Cancer"},{"key":"933_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/icb.2017.6","volume":"95","author":"MC Ochoa","year":"2017","unstructured":"Ochoa, M. C. et al. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol. Cell Biol. 95, 347\u2013355 (2017).","journal-title":"Immunol. Cell Biol."},{"key":"933_CR11","doi-asserted-by":"publisher","first-page":"871085","DOI":"10.3389\/fonc.2022.871085","volume":"12","author":"T Annese","year":"2022","unstructured":"Annese, T., Tamma, R. & Ribatti, D. Update in TIGIT immune-checkpoint role in cancer. Front Oncol. 12, 871085 (2022).","journal-title":"Front Oncol."},{"key":"933_CR12","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/cancers15102718","volume":"15","author":"DC Ziogas","year":"2023","unstructured":"Ziogas, D. C. et al. Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers. 15, 2718 (2023).","journal-title":"Cancers."},{"key":"933_CR13","doi-asserted-by":"publisher","first-page":"ltad009","DOI":"10.1093\/immadv\/ltad009","volume":"3","author":"AJ Patel","year":"2023","unstructured":"Patel, A. J. & Middleton, G. W. TIGIT-based immunotherapeutics in lung cancer. Immunother. Adv. 3, ltad009 (2023).","journal-title":"Immunother. Adv."},{"key":"933_CR14","doi-asserted-by":"publisher","first-page":"105472","DOI":"10.1016\/j.oraloncology.2021.105472","volume":"121","author":"L Mao","year":"2021","unstructured":"Mao, L. et al. TIGIT\/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells. Oral. Oncol. 121, 105472 (2021).","journal-title":"Oral. Oncol."},{"key":"933_CR15","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.3390\/cancers14235757","volume":"14","author":"A Pawlowska","year":"2022","unstructured":"Pawlowska, A. et al. The Dual Blockade of the TIGIT and PD-1\/PD-L1 pathway as a new hope for ovarian cancer patients. Cancers. 14, 5757 (2022).","journal-title":"Cancers."},{"key":"933_CR16","first-page":"1","volume":"14","author":"D Brazel","year":"2023","unstructured":"Brazel, D., Ou, S. I. & Nagasaka, M. Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer 14, 1\u20139 (2023).","journal-title":"Lung Cancer"},{"key":"933_CR17","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/14737140.2023.2247565","volume":"23","author":"P Rutkowski","year":"2023","unstructured":"Rutkowski, P. & Czarnecka, A. M. Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma. Expert Rev. Anticancer Ther. 23, 897\u2013902 (2023).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"933_CR18","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1080\/14656566.2016.1258056","volume":"17","author":"E Tenti","year":"2016","unstructured":"Tenti, E. et al. Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML. Expert Opin. Pharmacother. 17, 2479\u20132486 (2016).","journal-title":"Expert Opin. Pharmacother."},{"key":"933_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/CAD.0000000000001594","volume":"35","author":"C Ma","year":"2024","unstructured":"Ma, C. et al. Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review. Anticancer Drugs 35, 548\u2013555 (2024).","journal-title":"Anticancer Drugs"},{"key":"933_CR20","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.3389\/fimmu.2019.02226","volume":"10","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z. & Zhou, X. Foxp3 Instability Helps tTregs Distinguish Self and Non-self. Front Immunol. 10, 2226 (2019).","journal-title":"Front Immunol."},{"key":"933_CR21","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.4049\/jimmunol.1801400","volume":"202","author":"A Lahmann","year":"2019","unstructured":"Lahmann, A. et al. Bach2 Controls T Follicular Helper Cells by Direct Repression of Bcl-6. J. Immunol. 202, 2229\u20132239 (2019).","journal-title":"J. Immunol."},{"key":"933_CR22","doi-asserted-by":"publisher","first-page":"104495","DOI":"10.1016\/j.critrevonc.2024.104495","volume":"204","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Liu, W. & Wu, T. TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?. Crit. Rev. Oncol. Hematol. 204, 104495 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"933_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1200\/JCO.23.01891","volume":"42","author":"S Park","year":"2024","unstructured":"Park, S. et al. Phase III, randomized study of Atezolizumab Plus Bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04). J. Clin. Oncol. 42, 1241\u20131251 (2024).","journal-title":"J. Clin. Oncol."},{"key":"933_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho, B. C. et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 23, 781\u2013792 (2022).","journal-title":"Lancet Oncol."},{"key":"933_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","volume":"33","author":"J Niu","year":"2022","unstructured":"Niu, J. et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. Ann. Oncol. 33, 169\u2013180 (2022).","journal-title":"Ann. Oncol."},{"key":"933_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF01543103","volume":"15","author":"S Romagnani","year":"1995","unstructured":"Romagnani, S. Biology of human TH1 and TH2 cells. J. Clin. Immunol. 15, 121\u2013129 (1995).","journal-title":"J. Clin. Immunol."},{"key":"933_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11632-9","volume":"10","author":"N Marquardt","year":"2019","unstructured":"Marquardt, N. et al. Unique transcriptional and protein-expression signature in human lung tissue-resident NK cells. Nat. Commun. 10, 3841 (2019).","journal-title":"Nat. Commun."},{"key":"933_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/cancers16030496","volume":"16","author":"A Verma","year":"2024","unstructured":"Verma, A. et al. Nivolumab Plus 5-Azacitidine in pediatric relapsed\/refractory Acute Myeloid Leukemia (AML): Phase I\/II trial results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers. 16, 496 (2024).","journal-title":"Cancers."},{"key":"933_CR29","doi-asserted-by":"publisher","first-page":"1410638","DOI":"10.3389\/fimmu.2024.1410638","volume":"15","author":"L Ricard","year":"2024","unstructured":"Ricard, L. et al. A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed\/refractory AITL. Front. Immunol. 15, 1410638 (2024).","journal-title":"Front. Immunol."},{"key":"933_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver, N. et al. Efficacy, safety, and biomarkers of response to Azacitidine and Nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, Phase II study. Cancer Discov. 9, 370\u2013383 (2019).","journal-title":"Cancer Discov."},{"key":"933_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01302-6","volume":"20","author":"YJ Dai","year":"2021","unstructured":"Dai, Y. J. et al. Bone marrow infiltrated natural killer cells predicted the anti-leukemia activity of MCL1 or BCL2 inhibitors in acute myeloid leukemia. Mol. Cancer 20, 8 (2021).","journal-title":"Mol. Cancer"},{"key":"933_CR32","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"933_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1126\/sciadv.abh2169","volume":"7","author":"M Karlsson","year":"2021","unstructured":"Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci Adv. 7, 1275 (2021).","journal-title":"Sci Adv."},{"key":"933_CR34","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281.e24 (2019).","journal-title":"Cell"},{"key":"933_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"933_CR36","doi-asserted-by":"publisher","first-page":"W170","DOI":"10.1093\/nar\/gkn294","volume":"36","author":"Y Kumaki","year":"2008","unstructured":"Kumaki, Y., Oda, M. & Okano, M. QUMA: quantification tool for methylation analysis. Nucleic Acids Res 36, W170\u2013W175 (2008).","journal-title":"Nucleic Acids Res"},{"key":"933_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jcyt.2014.08.003","volume":"17","author":"R Alnabhan","year":"2015","unstructured":"Alnabhan, R., Madrigal, A. & Saudemont, A. Differential activation of cord blood and peripheral blood natural killer cells by cytokines. Cytotherapy 17, 73\u201385 (2015).","journal-title":"Cytotherapy"},{"key":"933_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70, 440\u2013446 (2010).","journal-title":"Cancer Res"},{"key":"933_CR39","doi-asserted-by":"publisher","first-page":"100729","DOI":"10.1016\/j.omto.2023.100729","volume":"31","author":"NI Khushalani","year":"2023","unstructured":"Khushalani, N. I. et al. Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment. Mol. Ther. Oncolytics 31, 100729 (2023).","journal-title":"Mol. Ther. Oncolytics"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00933-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00933-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00933-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T10:18:29Z","timestamp":1747304309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-00933-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-00933-6","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}